Thomas Uldrick, M.D.
HIV and AIDS Malignancy Branch
Retroviral Disease Section
National Cancer Institute
9000 Rockville Pike
Building 10, Room 6N106
Bethesda, MD 20892
Dr. Uldrick received his B.A. from the University of California at Berkeley, and his M.D. from the State University of New York, Downstate. He trained in internal medicine, hematology, and medical oncology at Columbia University. At Columbia, he completed an M.S. in biostatistics, with a focus on patient-oriented research, under a scholarship funded by an NIH-sponsored Clinical and Translational Science Award. Through the NIH-sponsored Fogarty program, he collaborated with Kaposi sarcoma (KS) researchers in South Africa on issues related to treatment of advanced KS in resource-limited settings. He has served on the NCI Lymphoma Steering Committee Primary Central Nervous System Lymphoma Working Group and participates on the AIDS Clinical Trials Group Independent Endpoint Review Committee for trials investigating KS therapies in sub-Saharan Africa.
His current research focuses on novel approaches to the treatment of virally associated AIDS malignancies. Active projects include: (1) translation of preclinical observations regarding KSHV lytic activation as well as VEGF and IL-6 dysregulation in KSHV-associated malignancies into targeted early-phase treatment studies in multicentric Castleman’s disease and KS and (2) evaluation of radiation-sparing chemotherapeutic approaches for HIV-associated primary CNS lymphoma.
Dr. Uldrick's Clinical Trial(s):
NCI’s Center for Cancer Research (CCR) is currently conducting the following trial(s) for patients with HIV/AIDS-associated cancers and related diseases or multicentric Castleman disease and associated conditions. Click on the trial(s) below for additional details, including a summary of key eligibility criteria, study outline, and information on how to contact the study team directly.